Patents by Inventor Annette Deynet-Vucenovic

Annette Deynet-Vucenovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE
    Publication number: 20120309969
    Abstract: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 6, 2012
    Inventors: André Bubendorf, Annette Deynet-Vucenovic, Ralph Diodone, Olaf Grassmann, Kai Lindenstruth, Emmanuel Pinard, Franziska E. Rohrer, Urs Schwitter
  • SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE
    Publication number: 20110295007
    Abstract: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: July 22, 2011
    Publication date: December 1, 2011
    Inventors: Andre Bubendorf, Annette Deynet-Vucenovic, Ralph Diodone, Olaf Grassmann, Kai Lindenstruth, Emmanuel Pinard, Franziska E. Rohrer, Urs Schwitter
  • Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone
    Patent number: 8039473
    Abstract: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: October 18, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Andre Bubendorf, Annette Deynet-Vucenovic, Ralph Diodone, Olaf Grassmann, Kai Lindenstruth, Emmanuel Pinard, Franziska E. Rohrer, Urs Schwitter
  • SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE
    Publication number: 20100311971
    Abstract: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: July 22, 2010
    Publication date: December 9, 2010
    Inventors: Andre Bubendorf, Annette Deynet-Vucenovic, Ralph Diodone, Olaf Grassmann, Kai Lindenstruth, Emmanuel Pinard, Franziska E. Rohrer, Urs Schwitter
  • SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE
    Publication number: 20090215826
    Abstract: The invention is concerned with crystalline forms or amorphous forms of a pyrrolidine-3,4-dicarboxamide derivative, which is useful as an active ingredient of medicaments for the diseases which can be treated by the coagulation factor Xa inhibitors.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 27, 2009
    Inventors: Jean-Michel Adam, Andre Bubendorf, Annette Deynet-Vucenovic, Pascal Dott, Alexander Glomme, Olaf Grassmann, Wolfgang Haap, Martin Kuentz, Roland Meier
  • SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE
    Publication number: 20080214561
    Abstract: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: December 19, 2007
    Publication date: September 4, 2008
    Inventors: Andre Bubendorf, Annette Deynet-Vucenovic, Ralph Diodone, Olaf Grassmann, Kai Lindenstruth, Emmanuel Pinard, Franziska E. Rohrer, Urs Schwitter